261 related articles for article (PubMed ID: 23872835)
1. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
Asano K; Tanaka A; Sato T; Uyama Y
Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
[TBL] [Abstract][Full Text] [Related]
2. PMDA's challenge to accelerate clinical development and review of new drugs in Japan.
Ichimaru K; Toyoshima S; Uyama Y
Clin Pharmacol Ther; 2010 Oct; 88(4):454-7. PubMed ID: 20856242
[TBL] [Abstract][Full Text] [Related]
3. Clinical development and review times for new drugs in Japan: associated factors.
Ishibashi T; Yasuda K; Kusama M; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Oct; 88(4):487-91. PubMed ID: 20739921
[TBL] [Abstract][Full Text] [Related]
4. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
Tanaka M; Nagata T
Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
[TBL] [Abstract][Full Text] [Related]
5. Multi-regional clinical trials--what are the challenges?
Wang SJ
Pharm Stat; 2010; 9(3):171-2. PubMed ID: 20821408
[No Abstract] [Full Text] [Related]
6. Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies.
Ishibashi T; Kusama M; Sugiyama Y; Ono S
J Clin Pharm Ther; 2012 Dec; 37(6):657-63. PubMed ID: 22734557
[TBL] [Abstract][Full Text] [Related]
7. Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective.
Ando Y; Hamasaki T
Pharm Stat; 2010; 9(3):190-200. PubMed ID: 20737442
[TBL] [Abstract][Full Text] [Related]
8. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
9. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
[TBL] [Abstract][Full Text] [Related]
10. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
Tuffs A
BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
[No Abstract] [Full Text] [Related]
11. [Current PMDA Activities for Use of Biomarkers in Drug Evaluation].
Ishiguro A
Yakugaku Zasshi; 2015; 135(5):681-4. PubMed ID: 25948301
[TBL] [Abstract][Full Text] [Related]
12. New drug approval times and clinical evidence in Japan.
Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
[TBL] [Abstract][Full Text] [Related]
13. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
[TBL] [Abstract][Full Text] [Related]
14. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
Honig PK
Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
[TBL] [Abstract][Full Text] [Related]
15. Indian Supreme Court halts approval of new clinical trials until regulatory framework is set up.
Bagcchi S
BMJ; 2013 Oct; 347():f5996. PubMed ID: 24097130
[No Abstract] [Full Text] [Related]
16. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
[TBL] [Abstract][Full Text] [Related]
17. The European Medicines Agency's plans for sharing data from clinical trials.
Groves T; Godlee F
BMJ; 2013 May; 346():f2961. PubMed ID: 23657192
[No Abstract] [Full Text] [Related]
18. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials in "emerging markets": regulatory considerations and other factors.
Singh R; Wang O
Contemp Clin Trials; 2013 Nov; 36(2):711-8. PubMed ID: 24070788
[TBL] [Abstract][Full Text] [Related]
20. [Development and evaluation of new drugs and medical devices in Japan--standpoint of regulatory agency].
Maruyama H; Kondo T
Brain Nerve; 2010 Mar; 62(3):263-8. PubMed ID: 20297731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
